Clinical Trial Detail

NCT ID NCT03875235
Title A Global Phase III Study of Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

biliary tract cancer

Therapies

Cisplatin + Gemcitabine

Cisplatin + Durvalumab + Gemcitabine

Age Groups: adult senior

No variant requirements are available.